Prosight Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-33,220
Closed -$6.54M 44
2022
Q3
$6.54M Buy
33,220
+5,720
+21% +$1.23M 3.5% 9
2022
Q2
$5.88M Sell
27,500
-4,000
-13% -$977K 4.64% 8
2022
Q1
$8.95M Buy
31,500
+16,019
+103% +$4.94M 5.78% 5
2021
Q4
$5.83M Buy
+15,481
New +$6.01M 3.49% 11

Other funds holding CRL

Prosight Management's CRL Position: Q4 2022 in Review

Prosight Management sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 33,220 shares — an estimated $6.54M sold.

Prosight Management first reported a position in CRL in Q4 2021 and held it in 4 quarters. The position peaked at $8.95M in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Prosight Management reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Prosight Management sold 33,220 Charles River Laboratories shares in Q4 2022, an estimated $6.54M.
  • Prosight Management first reported a position in Charles River Laboratories in Q4 2021 and held it in 4 quarters.
  • Prosight Management's Charles River Laboratories position peaked at $8.95M in Q1 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.